REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter. Financial Results “Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the
